Solange Peters, MD, PhD, on Managing Toxicities of Checkpoint Inhibitors and Chemotherapy Regimens in NSCLC

Posted: Monday, October 7, 2019

Solange Peters, MD, PhD, of the Oncology Department of CHUV, discusses the differences, in terms of administering and monitoring toxicities, between a combination checkpoint inhibitor regimen and a combination chemotherapy regimen, and which treatment may be more tolerable for patients with non–small cell lung cancer.